GGrantIndex
Sort

64,565 grants matching drug discovery

Harvard-wide Program on Antibiotic Resistance

$1,980,896
Michael S. Gilmore · Massachusetts Eye And Ear Infirmary · P01 · FY2017 · AI

CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS

$1,980,477
University Of Kansas Lawrence · P20 · FY2002 · RR

Small molecule inhibitors of CAPON-induced tau aggregation

$1,980,378
Moustafa Gabr · Weill Medical Coll Of Cornell Univ · RF1 · FY2024 · AG

Orbitrap Astral to support investigator proteomics research in a Core facility.

$1,980,309
Tukiet T Lam · Yale University · S10 · FY2025 · OD

ADULT AIDS CLINICAL TRIALS UNIT

$1,980,025
Ohio State University · U01 · FY2005 · AI

Identification of Cell Type-Specific Actions of Antipsychotic Drugs

$1,979,996
Paul Greengard · Rockefeller University · P50 · FY2012 · MH

Identification of Cell Type-Specific Actions of Antipsychotic Drugs

$1,979,996
Paul Greengard · Rockefeller University · P50 · FY2014 · MH

PAAR-Pharmacogenomics of Anticancer Agents Research Group

$1,979,869
Mark J Ratain · University Of Chicago · U01 · FY2012 · GM

Molecular Targets COBRE

$1,978,806
Donald M Miller · University Of Louisville · P20 · FY2008 · RR

Identification of Cell Type-Specific Actions of Antipsychotic Drugs

$1,978,310
Paul Greengard · Rockefeller University · P50 · FY2011 · MH

CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS

$1,978,280
University Of Kansas Lawrence · P20 · FY2003 · RR

Initiation of DNA Replication in Mammalian Cells

$1,977,132
Mirit Aladjem · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

SPORE in Ovarian Cancer

$1,976,958
Ie-Ming Shih · Johns Hopkins University · P50 · FY2020 · CA

Pharmacogenomic Evaluation of Antihypertensive Responses

$1,976,439
Julie A. Johnson · University Of Florida · U01 · FY2011 · GM

CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS

$1,976,012
University Of Kansas Lawrence · P20 · FY2004 · RR

Harvard-wide Program on Antibiotic Resistance

$1,975,237
Michael S. Gilmore · Massachusetts Eye And Ear Infirmary · P01 · FY2019 · AI

Pharmacogenomic Evaluation of Antihypertensive Responses

$1,975,100
Julie A. Johnson · University Of Florida · U01 · FY2014 · GM

Data Coordination Center for PDX Net

$1,974,874
Jeffrey Hsu-Min Chuang · Jackson Laboratory · U24 · FY2017 · CA

DEVELOPMENTAL BIOLOGY OF HUMAN ERYTHROPOIESIS

$1,974,140
Stuart H Orkin · Boston Children'S Hospital · P01 · FY2015 · HL

Structure-based Discovery of Critical Vulnerabilities of Micobacteria

$1,973,398
James C Sacchettini · Texas A&M University · P01 · FY2012 · AI

Therapeutics for inflammatory bowel disease from the microbiome

$1,973,386
Sarkis K Mazmanian · Symbiotix Biotherapies, Inc. · R42 · FY2016 · DK

Development of novel therapeutics for opioid dependence

$1,972,485
Paul J Kenny · Icahn School Of Medicine At Mount Sinai · UH3 · FY2021 · DA

Development of novel therapeutics for opioid dependence

$1,972,485
Paul J Kenny · Icahn School Of Medicine At Mount Sinai · UH3 · FY2022 · DA

Development of novel therapeutics for opioid dependence

$1,972,485
Paul J Kenny · Icahn School Of Medicine At Mount Sinai · UG3 · FY2019 · DA

Development of novel therapeutics for opioid dependence

$1,972,485
Paul J Kenny · Icahn School Of Medicine At Mount Sinai · UH3 · FY2020 · DA